News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

EULAR Release: First Biomarkers Found To Predict Severe Osteoarthritis



6/11/2014 11:22:12 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Paris, France, 11 June 2014: The results of a study presented today at the European League Against Rheumatism Annual Congress (EULAR 2014) identify a correlation between the presence of biomarkers in the blood, known as micro RNAs (miRNAs), and the development of severe osteoarthritis (OA) of the knee or hip joint. The findings suggest that miRNAs may be used as biomarkers to predict severe OA disease in individuals.2

Preventative measures and early treatments are considered to be the most effective way of managing OA, but to date there has been no way of identifying the disease early on.2

“These results indicate that for the first time we will be able to predict the risk of severe osteoarthritis, before the disease starts to significantly impact a person’s life, allowing us to take preventative action early on. Through the early identification of osteoarthritis we can decrease both the impact of the disease on individuals and the major socio-economic burden severe disease poses,” said Dr Christian Beyer, lead author from University of Erlangen-Nuremberg, Germany.

OA is a common musculoskeletal disorder affecting 10% of the world’s population.3 It is characterised by pain and stiffness in the joints and is one of the top ten most disabling diseases in developed countries,4 posing a major cause of knee or hip replacements.5 Disability from the disease has a great impact on individuals, healthcare systems and society, contributing to loss of productivity and inability to work. The average total annual cost of OA per patient is between €1,330 and €10,452 across Europe.6 With risk factors including advancing age and obesity, the burden of the disease is expected to grow.7

This study screened existing serum samples of people with OA, through which they identified three potential miRNA markers. 816 patients were followed over 15 years and measured for the presence of the 374 miRNAs and the occurrence of OA, using joint replacement (known as arthroplasty), as a definitive outcome of severe OA in the knee or hip. Of the 816 patients, 67 patients had one or more total joint replacements for severe knee or hip OA. The results of serum analysis showed a correlation between severe knee or hip OA and three miRNA molecules known as let-7e, miR-454 and miR-885-5p. These results indicate those miRNAs could be used as biomarkers to predict severe OA.

This is the first study to identify differentially expressed miRNAs in osteoarthritis patients necessitating arthroplasty, in a large population-based cohort using the well-defined Bruneck cohort.

For further information on this study, or to request an interview with the study lead, please contact us via: EULAR congress Press Office: Room 104, Palais des congrès de Paris Email: eularpressoffice@cohnwolfe.com Onsite tel: +44 (0) 7880 173209 Twitter: @EULAR_Press

About EULAR

The European League Against Rheumatism (EULAR) is an umbrella organisation which represents scientific societies, health professional associations and organisations for people with rheumatic diseases throughout Europe.

EULAR aims to promote, stimulate and support the research, prevention, and treatment of rheumatic diseases and the rehabilitation of those it affects.

With 45 scientific member societies, 35 People with Arthritis and Rheumatism in Europe (PARE) organisations, 17 health professionals associations and 26 corporate members, EULAR highlights the importance of combating rheumatic diseases through both medical means and patient care.

EULAR 2014 is set to be the biggest rheumatology event in Europe with almost 14,000 scientists, physicians, allied health professionals and related audiences in attendance from 130 countries. Over the course of the congress there will be 302 oral and 1,806 poster abstract presentations, 155 sessions, 725 lectures, 33 poster tours with 421 invited speakers. To find out more about the activities of EULAR, visit: www.eular.org

1 Felson DT, Lawrence RC, Dieppe PA et al. Osteoarthritis: new insights. Part 1: the disease and its risk factors. Ann Intern Med. 2000;133:635-646
2 Beyer C, Zampetaki A, Lin N-Y et al. Signature of circulating micrornas in osteoarthritis. EULAR 2014, Paris. OP0003
3 Helmick CG, Felson DT, Lawrence RC et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part 1. Arthritis Rheum. 2008;58:15-25
4 OECD iLibrary. Health at a Glance: Europe 2012. http://www.oecd-ilibrary.org/sites/9789264183896-en/03/10/index.html?itemId=/content/chapter/9789264183896-37-en [Accessed 05/06/2014]
5 Arthritis Research UK. Data and statistics on osteoarthritis. http://www.arthritisresearchuk.org/arthritis-information/data-and-statistics/osteoarthritis.aspx [Accessed 05/06/2014]
6 Hiligsmann M, Reginster JY. The economic weight of osteoarthritis in Europe. Medicographia. 2013;35:197-202
7 Cross M, Smith E, Hoy D et al. Clinical and epidemiological research: Extended report: The global burden of hip and knee osteoarthritis: estimates from the Global Burden of Disease 2010 study. Ann Rheum Dis. doi:10.1136/annrheumdis-2013-204763

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES